Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.
about
Structural and Functional Studies on the Interaction of Adenovirus Fiber Knobs and Desmoglein 2A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous routeCryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses.Low seroprevalent species D adenovirus vectors as influenza vaccines.A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide.Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX.Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.Chapter two--Adenovirus strategies for tissue-specific targeting.Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX.Transductional targeting of adenovirus vectors for gene therapyGenetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion.Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.Current advances and future challenges in Adenoviral vector biology and targetingAdenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer modelTargeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.Avidin-biotin technology in targeted therapy.Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.Unnatural amino acid incorporation onto adenoviral (Ad) coat proteins facilitates chemoselective modification and retargeting of Ad type 5 vectors.In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX.Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid.Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy.Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting.Targeting adenoviruses with factor x-single-chain antibody fusion proteinsDesigner Oncolytic Adenovirus: Coming of Age.
P2860
Q27679683-3937E7FB-DB25-4C75-BA69-1AEE69CABD30Q28817910-A76D4A7D-F783-445D-9F39-E2F23C8A0B7FQ29994714-365C2E50-61CC-4BC1-8EB4-BA0BE49EC7C2Q30353263-63C61F03-168D-4B39-A0ED-20342FE98BCCQ33711477-92BD7735-1A9E-4930-B86D-58971671B55AQ34120709-F5B5AE8F-2694-4943-AA8E-AD0D347044A6Q34123275-808392CC-D089-45B3-8A5D-1B4BB8801A7FQ34643252-2E85799E-B1C4-4F49-BA93-3115FB4CA708Q35140014-7FF42778-5AAB-40AC-BAA5-FC3122DB4C1CQ35609035-A8BC51F5-FA4B-4326-9F49-58CCAAF1898AQ35609066-5721A34D-418B-4DB2-879A-A535FFE010E2Q36387898-71C377CA-A772-4659-8944-76099E95D70DQ36463004-DEF11087-65A0-4A8F-A763-91FBCAE3D34EQ36535456-EE033764-1130-4EB0-82A1-5CD4BF332294Q37127836-D4615DFB-B81D-4AC8-AF9C-F3A21FE95722Q37227135-75F6949F-BCA4-4837-A3CA-5A52A958091AQ37710089-CED95768-8D57-452D-A293-42BEAC408CEAQ37806749-03A42EFB-BDAF-4C17-8A1A-BF20A2F5F56EQ38614156-B7E28066-3D1F-4F4C-A6D4-6B468A2492E3Q39033552-23F0D0AF-DE73-4A80-B3E6-61920B9B21E3Q39536450-A808C554-65FC-42BA-85CA-664B4857D2FFQ39946508-CFD2FDBF-20F0-4011-A213-2DD2CBA1F791Q40005191-CACCFD6B-1834-4045-BD8A-89DD068820EFQ40176311-5618888A-9108-4F95-A2F1-890F58BAE7CEQ41851585-6F61028C-8300-4E68-97B0-DDE069BE6974Q41875163-D68DFB83-9376-4169-B8F3-5497CB3903DBQ42533800-479F27C4-92B6-4723-8B94-5622F2C3EDD6Q55467684-F4E9750E-8200-47C9-848A-ED6EDB563BA2
P2860
Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Avidin-based targeting and pur ...... iotinylated adenoviral vector.
@ast
Avidin-based targeting and pur ...... iotinylated adenoviral vector.
@en
type
label
Avidin-based targeting and pur ...... iotinylated adenoviral vector.
@ast
Avidin-based targeting and pur ...... iotinylated adenoviral vector.
@en
prefLabel
Avidin-based targeting and pur ...... iotinylated adenoviral vector.
@ast
Avidin-based targeting and pur ...... iotinylated adenoviral vector.
@en
P2860
P1433
P1476
Avidin-based targeting and pur ...... biotinylated adenoviral vector
@en
P2093
M Brandon Parrott
Michael A Barry
P2860
P304
P356
10.1016/J.YMTHE.2004.03.006
P577
2004-06-01T00:00:00Z